ArticleFrontiers in immunology2026
Multi-dimensional integration of gene expression, protein evidence, and serum autoantibodies for diagnostic modeling in esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Esophageal squamous cell carcinoma (ESCC) accounts for most esophageal cancer cases. This study implemented a multi-dimensional integrative approach to identify tumor-associated autoantibodies (TAAbs) and develop a diagnostic model for the early detection of ESCC. Methods: The study comprised four phases: discovery, verification, modeling, and evaluation. Transcriptomic screening of public datasets and protein-level evidence from literature were integrated to identify candidate tumor-associated antigens (TAAs), followed by serological evaluation using enzyme-linked immunosorbent assay (ELISA) in 940 samples. Eight machine learning algorithms were assessed to develop the optimal diagnostic model. Results: In the discovery phase, transcriptomic analysis identified 26 differentially expressed genes in ESCC, of which ten genes encoding proteins with literature-supported evidence were selected as candidate TAAs for serological testing. Seven TAAbs were significantly elevated in ESCC cases compared with normal controls in the verification phase. In the modeling phase, six TAAbs (anti-CEP55, anti-CKS1B, anti-ECT2, anti-KIF2C, anti-SURV, and anti-TPX2) remained elevated in ESCC cases compared with both benign esophageal disease and normal controls. The support vector machine (SVM) model demonstrated the best diagnostic performance, achieving AUCs of 0.826 (95% CI: 0.776-0.876) in the training set and 0.741 (95% CI: 0.651-0.832) in the internal test set. In the evaluation phase, the SVM model was validated in an independent temporal test set (AUC 0.779, 95% CI 0.717-0.842). The web-based diagnostic tool is accessible at https://linzou.shinyapps.io/ESCC_SVM_Model/. Conclusion: This multi-dimensional approach linking transcriptomic evidence, protein-level validation, and immunodiagnostic markers facilitated the development of a diagnostic model, which may hold promise for early detection of ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.